Epidermal growth factor receptor-mutated lung carcinomas with insufficient response to epidermal growth factor receptor inhibitors

• Published in: Future oncology (London, England) Vol. 20; no. 31; pp. 2397 - 2407
• Main Authors: Moiseenko, Fedor, Kuligina, Ekaterina, Elsakova, Ekaterina, Imyanitov, Evgeny
• Format: Journal Article
• Language: English
• Published: England 2024
• Subjects: Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; Circulating Tumor DNA - blood; Circulating Tumor DNA - genetics; Drug Resistance, Neoplasm - genetics; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Mutation; Protein Kinase Inhibitors - therapeutic use; Treatment Outcome; lung cancer; tyrosine kinase inhibitors; targeted therapy; EGFR mutations; prognostic factors; non–small cell lung carcinoma

Administration of single-agent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is a standard treatment option for metastatic non-small cell lung carcinomas with EGFR exon 19 deletions (ex19del) and L858R substitutions. However, there is a significant interpatient heterogene...